CoAxia has enrolled the final patient in the pivotal SENTIS trial of its NeuroFlo technology for treating ischaemic stroke. The company plans to finish analysing the results by the third quarter and, if positive, to then submit a premarket approval (PMA) application to the US FDA. ...
Please Login to read the full article.
